An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
VERDICT
The label
Markup
read at $3.73
MannKind Corporation holds its Markup at $3.73.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-13
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 16 days
Price
$3.73
Valuation
N/A trailing · 29.25 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.10
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$3.73
N/A P/E · 29.25 fwd
Our fair value
$5.15
38% discount
Analyst target (avg)
$7.50
+101% to current
Target low $4.75Analyst target rangeTarget high $13.00
▲ current $3.73 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$3.73
you are here
Conservative
$4.28
+15%
Analyst avg
$7.50
+101%
Our fair value
$5.15
+38%
Analyst high
$13.00
+249%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
42.90%
Profit margin
-11.08%
Analyst consensus
Strong Buy · 8 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its debt ratio. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 46.4% of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.6% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 14.3% of assets, under the 49% limit.Pass
Revenue purityOnly 2.3% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Biotech chasing diabetes relief still burns cash
Imagine a patient managing diabetes who needs reliable new treatments. MannKind develops options for that and other chronic conditions, yet it still reports a negative profit margin of 7 percent despite 15 percent revenue growth. With an unknown moat and an opportunity rating of none, the business does not clear our bar even though the ethical screen returns a pass.
The forward price to earnings sits at 20.9 times while eight analysts carry a strong buy consensus and a median target of 7 dollars against the current 4.03 dollar price. Our own fair value of 5.29 dollars implies some headroom, but the absence of a clear competitive edge leaves the story too thin to justify a position.
High execution risk remains the core issue in a field where late stage setbacks can erase years of progress. The numbers show promise on paper, yet without proven durability the setup stays speculative. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in MNKD's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
MNKD trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (8 analysts) rates it strong buy, with a mean price target of $7. Entered 2026-08-05 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-05Markup$4.03+10.1%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (8 analysts) rates it strong buy, with a mean price target of $7.
2026-07-18Markup$3.66+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (8 analysts) rates it strong buy, with a mean price target of $7.
2026-07-03Markup$3.66+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$3.66Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$3.36
+7.0%
·
$1,070
+7.0%
2 months
$2.57
+39.9%
·
$1,399
+39.9%
3 months
$2.82
+27.5%
·
$1,275
+27.5%
6 months
$5.81
-38.1%
·
$619
-38.1%
1 year
$3.92
-8.3%
·
$917
-8.3%
2 years
$4.49
-19.9%
·
$801
-19.9%
3 years
$4.03
-10.8%
·
$892
-10.8%
5 years
$4.05
-11.2%
·
$888
-11.2%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever MNKD does next, these words stay.
MannKind Corporation · MNKD · Markup · $3.73
Recorded 2026-08-13 · before the outcome · scored mechanically
